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Abstract
Inorganic arsenic (iAs) is a complete transplacental carcinogen in mice. Previous studies have
demonstrated that in utero exposure to iAs promotes cancer in adult mouse offspring, possibly
acting through epigenetic mechanisms. Humans and rodents enzymatically convert iAs to its
methylated metabolites. This reaction requires S-adenosylmethionine (SAM) as methyl group
donor. SAM is also required for DNA methylation. Supplementation with folate, a major dietary
source of methyl groups for SAM synthesis, has been shown to modify iAs metabolism and the
adverse effects of iAs exposure. However, effects of gestational folate supplementation on iAs
metabolism and fetal DNA methylation have never been thoroughly examined. In the present
study, pregnant CD1 mice were fed control (i.e. normal folate, or 2.2 mg/kg) or high folate diet
(11 mg/kg) from gestational day (GD) 5 to 18 and drank water with 0 or 85 ppm of As (as
arsenite) from GD8 to 18. The exposure to iAs significantly decreased body weight of GD18
fetuses and increased both SAM and S-adenosylhomocysteine (SAH) concentrations in fetal
livers. High folate intake lowered the burden of total arsenic in maternal livers but did not prevent
the effects of iAs exposure on fetal weight or hepatic SAM and SAH concentrations. In fact,
combined folate-iAs exposure caused further significant body weight reduction. Notably, iAs
exposure alone had little effect on DNA methylation in fetal livers. In contrast, the combined
folate-iAs exposure changed the CpG island methylation in 2,931 genes, including genes known to
be imprinted. Most of these genes were associated with neurodevelopment, cancer, cell cycle, and
signaling networks. The canonical Wnt-signaling pathway, which regulates fetal development,
was among the most affected biological pathways. Taken together, our results suggest that a
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combined in utero exposure to iAs and a high folate intake may adversely influence DNA
methylation profiles and weight of fetuses, compromising fetal development and possibly
increasing the risk for early-onset of disease in offspring.
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1. Introduction
Inorganic arsenic (iAs) is a common, naturally occurring drinking water contaminant (Smith
et al., 2000; Focazio et al., 2000). Millions of people around the world are exposed to iAs in
drinking water at levels that exceed the World Health Organization (WHO) recommended
limit of 10 μg of arsenic/L (10 ppb) (WHO, 2011). Chronic exposures to iAs are associated
with increased prevalence of skin cancer and cancers of internal organs (e.g., liver, bladder,
lung) (IARC 2004) and non-cancerous diseases such as diabetes, cardiovascular and
neurological disease (Navas-Acien, 2008; 2005; Del Razo, 2011; States, 2009; Gong, 2012;
Rosado, 2007; Tsai, 2003). The adverse health outcomes associated with iAs exposure are
determined in part by gender (Vahter, 2007), ethnicity (Vahter, 1995), level of exposure
(Gong, 2012; Valenzuela, 2009; Hopenhayn-Rich, 1998), and length of exposure
(Ehrenstein, 2005; Fernandez, 2012).
Population and laboratory studies indicate that early life exposure to iAs, including
intrauterine exposure, is associated with an increased risk of adverse health effects later in
life (Vahter, 2008; Waalkes, 2007; Tokar, 2012). Increased liver cancer mortality, associated
with in utero and/or early-life exposures to iAs, has been reported in Chile (Liaw, 1998). A
dose-related increase in hepatic and adrenal cancer in adult male offspring, and urogenital
cancer in adult female offspring of C3H and CD1 mice prenatally exposed to arsenite
(iAsIII), has been reported by Waalkes and associates (Waalkes, 2003, 2006a,b). Further
studies suggested that iAs acts as an endocrine disruptor (Shen, 2007) and/or affects DNA
methylation profiles in offspring (Liu, 2007). Thus, epigenetic mechanisms involving the
modulation of DNA methylation may underline the adverse effects of gestational exposure
to iAs.
It was shown that iAs methylation efficiency increases during the first trimester of
pregnancy (Gardner, 2010) and iAs and its metabolites readily cross the placenta and enter
the fetus (Concha, 1998; Rudge, 2009; Devesa, 2006; Jin, 2006). The biomethylation of iAs
is catalyzed by arsenic (+3 oxidation state) methyltransferase (AS3MT) that requires S-
adenosylmethionine (SAM) as methyl group donor, and endogenous reductants as cofactors
(Lin, 2002; Waters, 2004; Ding, ms accepted; Drobna, 2005; Drobna, 2006). In humans and
rodents, iAs is metabolized to monomethyl-, dimethyl-, and trimethyl-arsenic metabolites
(MAs, DMAs, and TMAs) that contain either trivalent (AsIII) or pentavalent (AsV) arsenic
(Challenger, 1945; Hayakawa, 2005). The liver is considered to be the most important site
for iAs biotransformation (Geubel, 1988; Buchet, 1984). The majority of the ingested iAs
and of its metabolites are excreted via urine (Fujisawa, 2007). In vitro and in vivo studies
have demonstrated that trivalent arsenicals are more toxic and reactive than their pentavalent
forms (Styblo, 2002; Drobna, 2005; Kitchin, 2008), and have longer half-life in tissues due
to their high-affinity for thiol groups (Hughes, 2008). Recent population studies showed
association between the presence of urinary trivalent methylated arsenic metabolites (MAsIII
and DMAsIII), and higher risk of premalignant skin lesions (Valenzuela, 2005) and
increased prevalence of diabetes (Del Razo, 2011) in individuals chronically exposed to iAs
in drinking water. The variations in urinary arsenical profiles of subjects exposed to iAs
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have been linked to genetic polymorphism in AS3MT (Agusa, 2011). However, other
factors such as age (Kurttio, 1998), sex (Lindberg, 2008), pregnancy (Hopenhayn, 2003a),
nutrition (Heck, 2007), and environmental exposures (Concha, 1998) were shown to
influence the metabolism of arsenic as well.
Suboptimal intake of nutrients that are essential for SAM synthesis, including methionine,
choline, folate, and vitamin B12, or the knockout of the folate receptor, have been shown to
impair iAs methylation and to increase susceptibility of laboratory animals to toxic and
carcinogenic effects of iAs exposure (Heck, 2007; Wlodarzczyk, 2001; Nelson, 2007).
Folate, a dietary precursor required for SAM synthesis, has been shown to modulate the
capacity to methylate iAs and the risk of diseases in individuals exposed to iAs in drinking
water. Plasma folate levels were found to be positively associated with the percentage of
urinary arsenic represented by DMAs, and negatively with the percentage represented by
MAs and iAs (Gamble, 2005). In addition, supplementation with folate enhanced iAs
methylation as indicated by an increase in the percentage of DMAs in urine (Gamble, 2006).
A similar increase in DMAs percentage found in urine of pregnant women is thought to be
associated with pregnancy rather than with plasma folate status (Gardner, 2011). Increased
iAs methylation during pregnancy was shown to be only marginally affected by nutritional
folate status (Li, 2008).
The periconceptional folic acid supplementation has been widely used to reduce the
incidence of congenital malformation and the risk of having premature or low birth weight
babies (Greenberg, 2011). The role of folic acid in one-carbon metabolism, as a participant
to the transfer of methyl groups, is considered to be critical for the development of placenta
and fetus, and for the epigenetic programming of fetal DNA (Zeisel, 2009). Thus, the
requirement for SAM in fetal development and in iAs detoxification may play a critical role
in determining the birth outcomes and the epigenetic onset of adult disease. Effects of in
utero exposure to iAs on gene-specific and genome-wide DNA methylation profiles in liver
of mouse fetuses have never been examined. In our study we used an established
transplacental model for iAs carcinogenesis (Waalkes, 2003) to evaluate the effects of
prenatal exposure to iAs on DNA and iAs methylation, and on one-carbon metabolism. We
also examined whether effects of iAs exposure in fetal livers can be modified by high folate
intake. Our data show that high folate intake does not prevent the low fetal body weights
associated with iAs exposure. In fact, it results in large changes in the DNA methylation of
genes involved in neurodevelopment and cell cycle, which may influence fetal and postnatal
development.
2. Material and Methods
2.1 Materials
Sodium meta-arsenite (iAsIII, 99% purity) was purchased from Sigma-Aldrich. An iAsIII
solution at the final concentration of 85 ppm of arsenic (As) provided to animals for
drinking was prepared in deionized water every three days to minimize oxidation of iAsIII to
pentavalent arsenate (iAsV). Arsenic is classified by the International Agency for Research
on Cancer as a human carcinogen. Therefore, necessary precautions are required during
handling to avoid exposure.
2.2 Animals, diet, and treatment
This study was approved by the UNC Institutional Animal Care and Use Committee
(IACUC). Primipregnant CD1 mice were purchased from Charles River Laboratories
(Wilmington, MA) at gestation day 1 (GD1) and housed in the University of North Carolina
at Chapel Hill (UNC-CH) Animal Facility, which is fully accredited by the American
Association for Accreditation of Laboratory Animal Care. The pregnant mice were housed
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individually in a climate-controlled environment with a 12 h light/dark cycle at 20–22°C and
50% relative humidity, and with unrestricted access to diet and water. Mice were fed a
control semi-purified AIN-76A diet (Dyets Inc., Bethlehem, PA) with 2.2 mg/kg of folate
(CT diet) or the same diet with 11 mg/kg of folate (FS diet). The level of folate in CT diet
has been shown to provide an adequate folate intake for rodents. Specifically, previous
studies showed that levels of folate in the liver, erythrocytes, and serum of mice fed a chow
containing 2 mg/kg of folate (Bills, 1992) resemble those found in humans with a normal
folate status (Hoppner and Lampi, 1980; Pietrzik, 2007; Rader, 2002). The relatively high
level of folate in the FS diet (11 mg/kg) has been used to test genetic mouse models for
neural tube defects for responsiveness to prenatal folate supplementation (Gray, 2009). This
level is five-fold higher than the adequate level for rodents and thus, it is consistent with the
upper level folate intakes of 5- to 10-times of the recommended dietary allowance (400 μg/
day) which has been used in human interventional trials (Malinow, 1997; Lin, 2004). Both
CT and FS diets contained 1.1 g/kg of choline chloride and 1% of succinyl sulfathiazole, an
inhibitor of folate production by gut bacteria. Animals drank either deionized water or water
containing 85 ppm of As as iAsIII. This concentration of iAsIII causes liver tumors in the
male offspring exposed in utero via drinking water (Waalkes, 2003). Pregnant mice (12
mice/group) were randomly assigned to the following treatment groups: CT group, mice
receiving CT diet from GD1 to 18 and deionized water from GD1 to 18; CT/iAs group, mice
receiving CT diet from GD1 to 18 and deionized water containing 85 ppm of As from GD8
to 18; FS group, mice receiving FS diet from GD5 to 18 and deionized water from GD1 to
18; and FS/iAs group, mice receiving FS diet from GD5 to 18 and deionized water
containing 85 ppm of As from GD8 to 18. Mice were monitored daily for signs of toxicity
and discomfort. Water and food consumption, and body weight were monitored over the
entire period of exposure. At GD18 venous blood from dams and liver tissues from dams
and fetuses were collected. Tails from fetuses were collected and the DNA was isolated after
Proteinase K (Qiagen) digestion, and phenol:chloroform:isopropyl alcohol (25:24:1, v/v;
Invitrogen) extraction was used for sex determination as described by Lambert et al. (2000).
Only livers collected from male fetuses were used in this study.
2.3 Analysis of arsenic species in liver and plasma samples
Arsenic species in maternal and fetal livers and in blood plasma were determined by hydride
generation-cryotrapping-atomic absorption spectrometry (HG-CT-AAS) (Hernández-Zavala,
2008; Currier, 2011). Briefly, 10% (w/v) liver homogenates prepared in deionized water
were microwave digested in ultrapure phosphoric acid (J.T. Baker, Phillipsburg NJ)
overnight. Aliquots of the digestates (50 μl each) were reduced with 2% cysteine (EMD
Chemicals Inc., Gibbstown, NJ), and analyzed for As species. Aliquots of blood plasma (50
μl each) were analyzed directly without digestion. The concentrations of total iAs (iAsIII +
iAsV), total MAs (MAsIII + MAsV), and total DMAs (DMAsIII + DMAsV) were calculated
using calibration curves prepared for standard iAsV, MAsV, DMAsV (0.5–2.0 ppb) reduced
with 2% cysteine.
2.4 Folate analysis
A microbiological assay based on the growth response of L. casei to folic acid (Tamura,
1990) was used to determine folate levels in maternal plasma, using services provided by the
Nutrition and Obesity Research Center (NORC) at UNC-Chapel Hill, NC. The plasma folate
levels were determined based on a calibration curve prepared by using a 5-
methyltetrahydrofolic acid (Sigma) as standard, within a concentration range of 10–200 pg.
2.5 S-adenosylmethionine and S-adenosylhomocysteine analysis
Levels of S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) were
determined by NORC using high-performance liquid chromatography (HPLC) as described
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by She et al. (1994). This method provides a rapid resolution of both SAM and SAH in a
single run by direct injection of the perchloric acid extract of tissue allowing reduction of
procedural and analytical errors in determination of SAM/SAH ratio. SAM and SAH
purchased from Sigma were used to prepare standard solutions and to generate calibration
curves.
2.6 DNA-methylation analysis
High-molecular-weight (20–150 kb) genomic DNA (gDNA) was isolated from fetal livers
after digestion with Proteinase K (Qiagen) using phenol:chloroform extraction followed by
isoamylalcohol precipitation. Isolated DNA was processed for microarray hybridization as
previously described (Yan, 2002). Briefly, two micrograms of gDNA were digested into
small (≤ 200 bp) fragments with MseI restriction enzyme (New England Biolabs (NEB),
Beverly, MA) that recognizes TTAA sites. The DNA fragments with cleaved ends purified
by QIAquick PCR Purification Kit (Qiagen, Germantown, MD) were ligated to
unphosphorylated linkers (H12: 5′-TAATCCCTCGGA-3′; H24: 5′-
AGGCAACTGTGCTATCCGAGGGAT-3′) using Fast Link Ligase (Epicentre, Madison,
WI), purified using QIAquick column (Qiagen) and vacuum-dried. The ligated DNA was
first digested with methylation-sensitive endonuclease BstUI (NEB) followed by second
digestion with methylation-sensitive endonuclease HpaII (NEB). The linker polymerase
chain reaction using H24 primer and Deep Vent(exo−) DNA polymerase (NEB) was then
used to amplify all methylated fragments of ligated DNA. PCR products were purified using
QIAquick column (Qiagen), vacuum-dried and shipped to the University Health Network
Microarray Centre (Toronto, Canada; http://www.microarrays.ca). Here, DNA samples were
labeled with fluorescence dyes (Cy3, Cy5) and hybridized to mouse 16k CpG-island
microarrays (Agilent). Each treatment group was hybridized against universal control
(genomic DNA isolated from the mouse liver) purchased from Biochain (Hayward, CA).
Arrays were washed then scanned using an Agilent G2565BA scanner, and quantified using
ArrayVision v. 8.0 (Imaging Research Inc.).
2.7 Quantitative PCR
Quantitative Real-Time PCR (qPCR) was used to examine the expression levels of genes
involved in iAs and one-carbon metabolism, DNA methylation, and of selected genes with
altered CpG island methylation. Mouse gene specific Taqman Gene Expression Assays and
Gene Assay Mix (Applied Biosystems) were used. qPCR was carried out on a Roche
LightCycler 480 system. The expression level of Gapdh transcript was used as an
endogenous reference for quantification. The fold-change in gene expression was calculated
using Comparative Ct Method (ΔΔCt method) described elsewhere (Livak, 2001).
2.8 Statistical analysis
The data collected from folate analysis, As speciation analysis, SAM and SAH analysis, and
quantitative PCR analysis were evaluated using Origin 7.5 software. Effects of diet and iAs
exposure, as well as interactions between diet and iAs exposure, were analyzed by analysis
of covariance. Differences between the treatment groups were evaluated by analyses of
variance (ANOVAs) with Bonferroni multiple-comparison post-hoc test. Values are
expressed as Mean ± S.E. for each treatment group (n = 7–11). The data with p<0.05 were
considered to be statistically significant.
Data generated by microarrays were pre-processed using Lowess normalization on a log[2]
scale. The normalized data were analyzed by Principal Component Analysis and the
Significance Analysis of Microarrays (Tusher, 2001), using the TM4 software Suite 4.6
(Saeed, 2003). Gene lists were corrected for a false discovery rate (FDR) threshold of 5%.
Network analysis was carried out using Ingenuity Software as described in recent studies
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(Fry, 2007; Smeester, 2011). Fisher’s exact test was used to calculate a p-value determining
the probability that the number of genes, whose DNA methylation was changed, within each
molecular network and biological function, is due to chance alone.
3. Results
3.1 Monitoring of animals
Maternal water and food consumption were monitored between GD8 to 18 and recorded
every three days until sacrifice. Dams exposed to 85 ppm of As in drinking water drank
~50% less water than mice in CT and FS groups (Fig. 1A). This observation is consistent
with our previous studies, showing that the lower water intake does not affect the hydration
status of the mice (Paul 2007, 2011). Based on the average water consumption between GD8
and GD18, mice in CT/iAs and FS/iAs groups ingested a total of 4.4 mg and 3.5 mg of As
over the entire study period (i.e., 440 μg and 350 μg As per day), respectively. Similarly,
mice receiving iAsIII in drinking water consumed significantly less (~15–20%) food than
mice drinking pure deionized water. However, there were no significant differences between
the treatment groups when the food consumption by dams was normalized for number of
fetuses. On average each dam consumed ~4 g of chow/fetus during the period of GD8–
GD18 (Fig. 1B). To make sure that the dietary folate was efficiently absorbed we measured
folate concentration in blood plasma. Mice fed the FS diet (11 mg folate/kg) had >5-times
higher plasma folate concentrations than did mice fed the CT diet (2.2 mg folate/kg).
Mice exposed to iAsIII were monitored daily for signs of toxicity and discomfort. Most mice
tolerated the exposure to 85 ppm As without obvious problems. Two dams in FS/iAs group
appeared lethargic with signs of vaginal bleeding noted at sacrifice. These mice ate and
drank similar amounts of food and water as did other mice in this treatment group. Each of
these two dams carried 15 fetuses. Fetuses dissected from these two dams were
underdeveloped considering the stage of pregnancy (GD18). Therefore, these fetuses were
not included in further analyses. Necropsies of other dams found no fetal abnormalities or
macroscopic lesions. On average, each of these dams carried 12.2 ± 2.3 fetuses, including
6.6 ± 2.4 male and 5.6 ± 2.8 female fetuses. The location of fetuses in uterine horn and fetal
body weights were recorded during dissection; placenta and internal organs of the dams
were also examined. On average, male fetuses in all treatment groups were heavier by 5–7%
than female fetuses. However, the body weights of fetuses in CT/iAs group were ~15%
lower as compared to CT and FS groups. High folate intake was associated with further
decrease in fetal weight in FS/iAs group (~25% lower than CT group; Fig. 1D). This
decrease was significantly different from all other treatment groups.
3.2 Maternal and fetal arsenical profiles
The concentrations of iAs metabolites in maternal and male fetal livers were determined by
HG-CT-AAS. We found that the average concentrations of total speciated As (i.e., sum of
iAs + MAs + DMAs) in fetal livers in the treatment groups exposed to iAs were 5–6 times
lower as compared to livers of dams (Fig. 2A, B). In addition, the composition of As species
in maternal and fetal livers differed. DMAs was the major As species detected in both
maternal and fetal livers, and represented approximately 40% and 60% of total As in livers
of dams from CT/iAs and FS/iAs groups, respectively, and ~80% in fetal livers from both
groups. High folate intake significantly decreased the amount of iAs (Fig. 2A), and
increased the methylation ratios of DMAs/MAs and (MAs+DMAs)/iAs in maternal livers
(Table 1). No significant differences in the total or speciated As were observed in fetal livers
from CT/iAs and FS/iAs groups (Fig. 2B). We also analyzed iAs metabolites in blood
plasma collected from dams. Notably, DMAs accounted for 91.2 and 92% of total As in
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plasma of CT/iAs and FS/iAs dams while MAs represented only 6.1 and 4.4%, respectively
(Fig. 2C).
3.3 SAM and SAH levels in fetal livers; one-carbon metabolism
We analyzed the concentrations of SAM and S-adenosylhomocysteine (SAH) in fetal livers
and calculated the transmethylation potential (i.e., SAM/SAH ratio). The average hepatic
SAM concentrations were higher in CT/iAs, FS, and FS/iAs groups as compared to CT
group (Fig. 3A). However, only the difference between CT and CT/iAs groups was
statistically significant at p<0.05. The hepatic SAH concentrations were also higher in all
treatment groups as compared to CT group, with statistically significant differences found
only for fetuses in CT/iAs and FS/iAs (Fig. 3B). The transmethylation potential represented
by SAM/SAH ratio was lower in all treatment groups as compared to CT fetuses, but these
differences were not significantly altered (Fig. 3C).
In addition to SAM and SAH concentrations, we analyzed mRNA levels for two enzymes
involved in one-carbon metabolism, specifically, methionine adenosyltransferase (Mat2a)
involved in SAM synthesis and S-adenosylhomocysteine hydrolase (Ahcy) participating in
SAH hydrolysis, a step that converts SAH to the adenosine and homocysteine (Hcy). Results
of quantitative PCR suggested a moderate, but not statistically significant increase in Mat2a
transcript as a result of iAs exposure and, particularly of high folate diet (Fig. 4A). Ahcy
mRNA levels were lower in livers of fetuses exposed to iAs as compared to fetuses in CT
and FS groups (Fig. 4B). However, these differences were not statistically significant. We
also examined mRNA levels for other enzymes involved in Hcy metabolism; 5-
methyltetrahydrofolate-homocysteine methyltransferase reductase (Mtrr) and cystathionine
β-synthase (Cbs). While the mRNA levels for Mtrr were not significantly different among
the treatment groups, Cbs mRNA levels were higher in livers of FS fetuses as compared to
other treatment groups (eFig. 1 in Supplemental Material). We further evaluated the
expression of methyltransferases involved in the utilization of methyl groups for DNA and
iAs methylation, including DNA (cytosine-5)-methyltransferase 1 (Dnmt1), DNA
(cytosine-5)-methyltransferase 3-alpha (Dnmt3a), and arsenic (+3 oxidation state)
methyltransferase (As3mt). There were no significant differences in Dnmt1 mRNA levels
among the treatment groups (data not shown). Dnmt3a mRNA level was significantly lower
in fetal livers from FS/iAs group as compared to CT group (Fig. 4C). Dnmt3a mRNA level
was also lower in CT/iAs fetuses, but this difference was not statistically significant.
Evaluation of mRNA and protein levels for As3mt did not reveal any significant differences
between treatment groups (data not shown).
3.4 DNA methylation pattern in fetal livers
CpG-island microarrays were used to assess effects of iAs exposure and high folate intake
on genomic DNA methylation profiles in fetal livers. Significance Analysis of Microarrays
with false discovery rate (FDR) threshold <5% identified significantly hyper-methylated and
hypo-methylated probes in FS and FS/iAs treatment groups. Compared to fetal livers from
CT group, the exposure to iAs alone altered the CpG-island methylation pattern of only four
DNA probes while high folate diet alone affected CpG-island methylation in 253 probes.
The most pronounced changes in DNA methylation pattern were found for the combined
high folate intake and exposure to iAs with 5,357 CpG-island probes showing significantly
altered methylation levels. The lists of significantly changed CpG-island probes generated
from Significance Analysis of Microarrays were used to identify corresponding genes,
molecular networks and biological pathways using Ingenuity software. There were 12 and
2,770 genes with uniquely altered methylation patterns in FS and FS/iAs group, respectively
(Fig. 5). Changes in the methylation pattern of 161 genes were shared by both these groups.
Among the 161 shared genes, 41 genes were associated with gene expression (p = 1.20 ×
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10−9) and 36 genes with embryonic development (p = 1.63 × 10−7). The gene expression and
embryonic development networks were also among the most affected networks in fetal
livers from FS/iAs group, considering all 2,931 genes with significantly altered methylation
pattern, with p-values of 1.85 × 10−99 and 1.40 × 10−74, respectively. Combined exposure to
iAs and folate also changed the methylation of genes associated with cancer and
neurodevelopment molecular networks (eTable 1 in Supplemental Material, Fig. 6A,B).
Notably, Wnt-signaling pathway was one of the most affected biological pathways in FS/iAs
group (Table 2, Fig. 7). We identified 58 genes with significantly altered methylation status
that are associated with the Wnt-signaling pathway (Wnt3, Fzd8, Fzd10, Dvl1, Dvl3, Axin2,
Ctnnb1) or regulate this pathway (Cdkn2a, Rara, Tgf-β). In addition, the combined high
folate diet and exposure to iAs affected the methylation patterns of CpG islands present in
differentially methylated regions (DMRs) of imprinted genes involved in the regulation of
embryogenesis and neural development (Gnas, Nnat, and Kcnk9) and imprinted genes
associated with cancer (Igf2r, Dlk1, Tssc4, Grb10, and Mest) (Table 3). CpGs were
identified as being in DMRs by using WAMIDEX, a Web Atlas of Murine Genomic
Imprinting and Differential Expression, King’s College, London (https://
atlas.genetics.kcl.ac.uk/atlas.php) and referenced previously (Arnaud, 2010).
4. Discussion
In our study we used the mouse model for transplacental arsenic carcinogenesis established
by of Dr. Waalkes’ group (2003, 2006b). They showed that the adult male offspring of CD1
mice, prenatally exposed to iAs (85 ppm As) in drinking water, developed hepatocellular
carcinoma (HCC). In addition, they found elevated levels of transcript for estrogen receptor
alpha (ER-α) and hypomethylation of its promoter in HCC (Waalkes, 2004). Adopting the
CD1 mouse model, our study examined effects of in utero exposure to iAs on gene-specific
methylation, using genome-wide DNA methylation profiling in male fetal livers, and the
role of high folate intake in modulating these effects.
The results of our study suggest that gestational exposure to iAs causes ~15% reduction in
male fetal body weight at GD18. These results are in agreement with previous population
studies from Chile (Hopenhayn, 2003b) and Taiwan (Yang, 2003) where lower birth weights
of neonates after in utero exposure to iAs were observed. Periconceptional folate
supplementation has been widely used to reduce the incidence of congenital malformations
and to prevent premature or low birth weight babies. Folate supplementation is also thought
to facilitate detoxification of iAs (Gamble, 2005; 2006; 2007; Hall, 2009). However, our
data suggest that, at least in mice, a high gestational folate intake (5-times above the
adequate folate level in rodent diet) does not prevent body weight loss caused by iAs
exposure. In fact, the high folate intake exacerbates the loss of body weight in iAs-exposed
fetuses.
Low birth weight babies (<2,500 g) are at a significant risk for perinatal mortality and
morbidity, and for the development of a broad range of diseases later in life, including
cancer (Spector, 2009), CVDs, obesity, diabetes (Barker, 2003), congenital abnormalities
(Spector, 2008), and learning disabilities (Lorenz, 1998; Saigal, 2000; Resnick, 1999). The
low birth weight percentile is etiologically heterogeneous and molecular determinants are
not well known. Gestational exposure to environmental pollutants and nutrients plays a
critical role in determining the birth outcomes (Kaur, 2010) and the epigenetic onset of adult
disease (Perera, 2011). Recent studies show an altered expression of imprinted genes in
placentas from growth restricted fetuses and from infants with low birth weight (McMinn,
2006; Apostolidou, 2007; Tabano, 2010). Thus, the fetal and postnatal development could
be negatively affected by epigenetic changes during gestation and by dysregulation of the
corresponding signaling and metabolic pathways. For example, the incidence of
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hepatoblastoma, a liver cancer, is strongly increased among children with very low birth
weight (Tanimura, 1998; Reynolds, 2004; McLaughlin, 2006).
The methylation of iAs by rat As3mt or human AS3MT requires SAM as methyl group
donor (Lin, 2002; Waters, 2004; Ding, ms submitted). While folate supplementation
facilitates iAs methylation in adults and children (Gamble, 2006; Hall, 2009), increased iAs
methylation during pregnancy was shown to be only marginally affected by nutritional
folate status (Gardner, 2011; Li, 2008). Liver is considered the main organ for iAs
methylation and the main site for folate storage and metabolism. In our study high folate
intake affected the retention of iAs, MAs, and DMAs only in maternal liver. Specifically,
folate significantly decreased the burden of iAs (p<0.002) and increased the amount of
DMAs in maternal livers, providing evidence that high folate intake plays a role in iAs
biotransformation. Higher levels of folate may increase the rate of the conversion of iAs to
DMAs as indicated by the first (MAs/iAs) and the second (DMAs/MAs) methylation ratios.
No such differences were observed in fetal livers. Notably, the profiles of methylated
arsenicals in fetal livers (i.e., percentage of total As represented by MAs and DMAs)
resembled MAs and DMAs profiles in maternal plasma, but not those in maternal liver. We
detected the presence of As3mt transcript in fetal livers but the level of As3mt protein
evaluated by immunoblot analysis was very low, suggesting low As3mt activity. Thus, it is
possible that the methylated arsenicals in fetal livers were transferred from maternal blood
across the placenta. In a population study from Bangladesh, Hall et al. (2007) reported
strong associations between maternal and cord blood arsenic metabolites, which provided
evidence that maternal-fetal transport of arsenic readily occurs and the fetus is exposed to a
complete spectrum of iAs metabolites.
Maternal plasma folate and homocysteine levels and/or polymorphisms in folate
metabolizing genes have been implicated in iAs metabolism and in susceptibility to iAs
toxicity (Hall, 2007; Engstrom, 2007). In our study, in utero exposures to iAs and folate
tended to increase SAM levels in fetal livers, as well as the expression of methionine
adenosyltransferase (Mat2a), an enzyme directly involved in SAM synthesis. Induction of
SAM synthesis in the groups exposed to iAs would be consistent with a compensatory
response to iAs exposure that increases the demand for methyl groups. An increase in SAM
level due to high folate diet should be expected as the folate is directly involved in SAM
synthesis. However, a significant increase in SAH levels accompanied by a decrease in the
transmethylation potential (SAM/SAH) in CT/iAs and FS/iAs groups indicated that the
efficiency of transmethylation reactions may be impaired due to reduced cellular
methylation capacity, and that high folate intake did not prevent these changes. Under
physiological conditions, SAH, a product of the transmethylation reactions and a potent
inhibitor of DNA methyltransferases, is further metabolized by S-adenosylhomocysteine
hydrolase (Ahcy) to homocysteine and adenosine. Lower levels of Ahcy transcript in the
livers of CT/iAs and FS/iAs fetuses may explain the higher levels of hepatic SAH in these
treatment groups as compared to controls.
Three DNA methyltransferase enzymes (DNMT1, DNMT3A, and DNMT3B) are involved
in active DNA methylation. DNMT1 catalyzes predominantly the methylation of
hemimethylated DNA, and thus is responsible for maintenance of DNA methylation pattern
(Takeshita, 2011). Both DNMT3A and DMNT3B function in de novo DNA methylation
(Sharma, 2011) and their expression is developmentally regulated. Most genomic targets can
be methylated by both DNMT3A and DNMT3B. However, DNMT3A is specifically
required for the methylation of imprinted genes in germ cells while DNMT3B methylates
the centromeric minor satellite repeats (Li, 2007). In our study, the combined maternal
exposure to iAs and high folate diet led to significant decrease in fetal Dnmt3a expression,
accompanied with changes in the CpG island methylation pattern of imprinted genes
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associated with cancer or with the regulation of embryogenesis and development (Table 3).
Dlk1 (Delta-like 1, paternally imprinted) is highly expressed in mouse embryos and placenta
during development, and plays a role as a growth factor responsible for maintaining cell
proliferation prior to differentiation (Yevtodiyenko, 2006). In our study, hypomethylation in
Dlk1 was associated with marginally significant increase (1.6 fold change; p=0.07) in
transcript level (eFig. 2). Upregulation of Dlk1 due to epigenetic events was also shown to
contribute to human hepatocellular carcinoma (Huang, 2007). Insulin-like growth factor
receptor (Igf2r) which is expressed only from maternal allele in mice is biallelically
expressed in humans. Igf2r functions as a tumor suppressor, thus it is expected that
incidence of cancers that results from its inactivation will be higher in mice than in humans.
Neuronatin, (Nnat) is expressed only from paternal allele and is involved in the regulation of
ion channels during brain development, in forming and maintaining the structure of the
nervous system, and in pituitary development and maturation (Wijnholds, 1995; Aikawa,
2003). Hypermethylation of its promoter has been associated with pituitary adenoma (Revill,
2009) as well as with pediatric leukemogenesis (Kuerbitz, 2002). Taken together, one could
speculate that aberrant DNA methylation patterns of imprinted genes might be responsible
for the epigenetic onset of disease not only in F1 generation but also in next generations, if
such changes would be also present in the primordial germ cells of F1, but further research
is needed.
Previous studies have linked epigenetic or gene expression changes to skin lesions in
subjects exposed to environmental iAs (Pilsner, 2009; Smeester, 2011) and suggested that
folate deficiency, hyperhomocysteinemia, and low urinary creatinine are risk factors
(Pilsner, 2009). Two studies have examined the link between prenatal arsenic exposure and
DNA methylation pattern of Alu, LINE-1 and LUMA, p16, and p53 genes in paired
maternal and umbilical cord leukocytes (Kile, 2012; Pilsner, 2012). A positive association
has been found between higher levels of iAs exposure and DNA methylation in LINE-1
repeated elements, and to a lesser degree within the promoter region of the tumor suppressor
gene p16 (Kile, 2012). In contrast, our study found no significant effects of iAs exposure on
genome-wide and gen-specific DNA methylation pattern in fetal livers. However, a wide
spectrum of genes with differentially altered methylation pattern has been identified after
intrauterine co-exposure of fetuses to iAs and a high level of dietary folate. Molecular
network analysis identified a large number of genes associated with cancer and
neurodevelopment. Further studies are needed to determine gene-specific methylation
profile in the brain tissues of fetuses exposed to iAs and folate. It has already been shown
that the prenatal and postnatal iAs exposure of Wistar rats caused significant changes in
promoter methylation of the genes involved in neuronal plasticity in the cortex and
hippocampus (Martinez, 2011). In addition, several studies examining the relationship
between iAs exposure and neurodevelopment in children showed reduced intellectual
function and decreased learning ability, attention, and memory (Wasserman, 2007; Rosado,
2007; Dakeishi, 2006). A range of behavioral and cognitive impairments in the offspring of
C57BL6/J mice prenatally exposed to iAs has been recently reported (Markowski, 2012).
These data demonstrate the need for further investigation of arsenic as neurotoxic agent and
its interactions with nutrient(s).
The WNT-pathway is one of the evolutionary conserved signaling pathways that regulate
the development of tissues and organs. Aberrant WNT-signaling has been linked to human
diseases such as cancer (Behari, 2010; Whittaker, 2010), type II diabetes (Bordonaro, 2009),
and neurological diseases (Hur, 2010). In our study, this pathway was one of the most
affected biological pathways in livers of FS/iAs fetuses. A recent study showed that
hypermethylation of WNT2 promoter downregulated its expression in placenta, and it was
associated with reduced fetal growth and low birth weight (Ferreira, 2011). In addition,
Crooked tail (Cd) mice, a model for neural tube defects (NTDs) bearing the point mutation
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in Lrp6, a co-receptor for canonical Wnt signaling, can be rescued by high dietary folate
level (10 ppm, i.e., 10 mg of folate per kg of diet). However, prenatal high folate intake
increased early lethality and NTDs in Lrp−/− embryos (Gray, 2010). Gene expression
analysis in these embryos found that folate and methionine metabolism, Wnt signaling,
mitochondrial function, and cytoskeletal regulation were among the significantly affected
pathways. In vitro experiments indicated that both deficiency and excess of folate had
deleterious impact on transcriptional activation by the canonical WNT signaling pathway in
NIH3T3 fibroblasts. Thus, it is possible that the epigenetic alterations of the genes involved
in WNT pathway regulation, observed in our study after combined iAs and folate exposures,
alter the expression of genes that affect Wnt signaling, possibly compromising fetal
development as demonstrated by low fetal body weights. For example, Mest, an imprinted
gene, has been shown to play an important role in embryo development, and to inhibit WNT
signaling through regulation of LRP6 glycosylation (Jung, 2011). In our study,
hypomethylation of Mest was observed in both FS and FS/iAs groups (Table 3). Thus, it is
possible that high folate intake may play a role in epigenetic regulation of LRP6
glycosylation and the presence of iAs in FS/iAs group may further pharmacologically
compromise WNT signaling, for example via interference with the maturation and plasma
membrane localization of LRP6.
In conclusion, this study is the first to indicate that in utero exposure of CD1 mice to iAs
combined with high gestational folate intake results in low fetal weight at GD18, dramatic
changes in global DNA methylation in fetal livers, and in aberrant CpG island methylation
of genes associated with fetal development and cancer networks. Further studies will be
needed to better understand implications of these findings for human populations chronically
exposed to iAs from the environment, particularly for pregnant women who may potentially
use high-dose folate supplements that are available over-the-counter to reduce the NTDs
risk.
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• We used transplacental CD1 mice model for inorganic arsenic (iAs)
carcinogenesis.
• We examined the effects of gestational iAs and high folate exposure on DNA
methylation.
• iAs-folate interaction resulted in low fetal weights and changes in DNA
methylation.
• Epigenetically altered genes were associated with cancer and
neurodevelopment.
• We showed that in utero iAs-folate interaction negatively affects fetal
development.
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Fig. 1. Consumption of water (A), food (B), maternal plasma folate level (C), and average fetal
weight (males and females) (D) at gestational day 18
Mean ± SE; the number (n) of dams n = 7 – 11 for A, B, and C; the number (n) of fetuses N
= 135–101 for D. *, #, o Denotes values that are significantly different from *CT, #CT/
iAs, oFS at p<0.05.
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Fig. 2. Arsenic species in maternal (A) and fetal (B) livers and in maternal plasma (C) at
gestational day 18
Mean values are shown for 7–11 dams and 7–10 fetuses.
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Fig. 3. SAM (A) and SAH (B) concentrations and SAM/SAH ratio (C) in fetal livers at
gestational day 18
Mean ± SE values are shown for 8–11 fetuses per treatment group. * Denotes significantly
different from *CT at p<0.05.
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Fig. 4. Relative expression (mRNA) levels for (A), Ahcy (B) and Dnmt3a (C) in fetal livers at
gestational day 18
Mean ± SE values are shown for 7 fetuses per treatment group. * Denotes significantly
different from *CT at p<0.05.
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Venn diagram depicting the number of genes with significantly altered methylation profiles
in fetal livers from FS and FS/iAs groups as compared to the control group (CT).
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The cancer-associated (A) and neurological development and function-associated (B)
molecular networks enriched for hypermethylated genes (in red) and hypomethylated genes
(in green) in FS/iAs treatment group.
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Fig. 7. The canonical Wnt pathway
WNT – WNT ligand; FRZ – Frizzled receptor; LRP – co-receptor; DSH – Dishevelled
receptor complex protein; Axin/GSK/APC – complex promoting degradation of β-catenin;
β-catenin – transcriptional co-activator; TCF/LEF – transcription factors.
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Table 1
Methylation ratios in CT/iAs and FS/iAs maternal livers.
MAs/iAs DMAs/MAs MAs+DMAs/iAs
CT/iAs
Average 0.71 1.60 1.87
SE 0.04 0.21 0.21
FS/iAs
Average 1.16 3.22 4.29
SE 0.31 0.62 0.75
p-value 0.08 0.01* 0.002*
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Table 2
Genes involved in Wnt-signaling pathway and significantly hypomethylated (green) or hypermethylated (red)
in the liver of fetuses after high folate intake (FS) and combined high folate intake with in utero exposure to
iAs (FS/iAs) as compared to the control (CT).
Wnt pathway Molecule D-score (FS) D-score (FS/iAs)











Dishevelled Dvl1 NA −5.25
Dvl3 NA 3.45
Axin Axin2 NA 3.15
B-catenin Ctnnb1 NA 3.67




Tcf/Lef Tcf12 NA 3.22
Note: D-score – Significance Analysis of Microarrays t-statistic value representing hypermethylated genes “+” and hypomethylated gene “−” as
compared to control group; NA – gene not detected as significantly changed; FS – group of animals on high folate diet; FS/iAs – group of animals
on high folate diet and receiving water containing arsenic.
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Table 3
Imprinted genes significantly hypomethylated (green) or hypermethylated (red) in livers of fetuses after high
folate intake (FS) and combined high folate intake and in utero exposure to iAs (FS/iAs).
Gene D-score (FS) D-score (FS/iAs) Expressed Allele Protein Description
Igf2r 6.47 5.34 Maternal Insulin-like growth factor receptor 2
Grb10 NA 3.76 Maternal (Isoform Dependent) Growth factor receptor-bound protein 10; binds to igf2r
Tssc4 NA −4.45 Maternal Tumor-suppressing candidate
Dlk1 NA −3.77 Paternal Tumor-suppressing candidate
Mest −4.91 −3.86 Paternal Member of alpha/beta hydrolase family; cancer and
development
Gnas NA 4.33 Maternal (Isoform Dependent) Neuroendocrine secretory protein 55
Nnat NA 6.08 Paternal Neuronatin; brain development
Kcnk9 −4.40 −3.75 Maternal Potassium channel; highly expressed in brain
Note: D-score – Significance Analysis of Microarrays t-statistic value representing hypermethylated genes “+” and hypomethylated gene “−” as
compared to control group (CT); NA – gene not detected as significantly changed; FS – mice on high folate diet; FS/iAs – mice on high folate diet
receiving water containing arsenic.
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